AstraZeneca to Sell Rights for Losec to Cheplapharm for Initial $243 Million

Date : 10/01/2019 @ 6:56AM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7217.0  -58.0 (-0.80%) @ 4:35PM
Astrazeneca share price Chart

AstraZeneca to Sell Rights for Losec to Cheplapharm for Initial $243 Million

Astrazeneca (LSE:AZN)
Historical Stock Chart

3 Months : From Sep 2019 to Dec 2019

Click Here for more Astrazeneca Charts.
   By Ian Walker 

AstraZeneca PLC (AZN.LN) said Tuesday that it is selling the rights to acid-reduction drug Losec to Cheplapharm Arzneimittel GmbH for an initial $243 million.

The pharmaceutical giant is selling the global commercial rights to Losec, excluding China, Japan, the U.S. and Mexico.

Under the deal Astra will receive milestone payments of up to $33 million in 2021 and 2022, subject to certain sales targets being met.

Astra said the sale, which is part of the board's strategy to reduce the portfolio of mature medicines, doesn't change its financial guidance for 2019.


Write to Ian Walker at


(END) Dow Jones Newswires

October 01, 2019 02:41 ET (06:41 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191215 22:03:29